The introduction of newer diabetes therapies has changed the diabetes paradigm across the world. n New Zealand this has resulted in decline in demand for PenMix® 30, PenMix® 50 and Mixtard® 30. Meeting this level of demand is not feasible. As a result, Novo Nordisk New Zealand has informed PHARMAC in Q4 2023 of its decision to discontinue supply of PenMix® 30, PenMix® 50 and Mixtard® 30 from 30 September 2024 onwards.

Read the full letter

In order to maintain transparency and ensure patient safety, in consultation with Medsafe, Novo Nordisk Pharmaceuticals Ltd (Novo Nordisk) is writing to inform you of a potential product manufacturing issue. Please note that this is not a recall of products.

Read the full letter

The recent and ongoing supply challenges of an alternative GLP-1 treatment have led to a rapid increase in VICTOZA® (liraglutide) demand beyond levels that can be supplied in the long term. This is due to the global supply challenges affecting all GLP-1 agonists.

Read the full letter